Mapi Pharma to Host Key Opinion Leader Meeting on Long Acting Glatiramer Acetate (GA Depot) for Multiple Sclerosis NESS ZIONA, Israel, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, clinical late stage biopharmaceutical company, announced today that it will host a Key Opinion Leader...

First Patient Treated in Mapi Pharma’s Phase II Clinical Trial of GA Depot for Primary Progressive Multiple Sclerosis (PPMS) Study is being conducted on strength of prior Phase II clinical trial that showed strong efficacy in RRMS patients who switched from Copaxone® to once-monthly GA Depot NESS ZIONA, Israel, Jan. 30,...

Mapi Pharma Announces Presentation of Phase II Results of Glatiramer Acetate Depot at ECTRIMS-ACTRIMS 2017 Congress in Paris Data Suggest that GA Depot Has Potential to Ease the Treatment Burden and Improve Patient Compliance in MS Patients on GA Depot Achieved a No Evidence of Disease Activity (NEDA) Score of 84.6% Phase...

Mapi Pharma Ltd. Announces Closing of $10 Million Investment NESS ZIONA, Israel, Aug. 17, 2017 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a privately held, fully integrated, clinical stage biopharmaceutical company has completed an investment round of $10 million...